Treatment validation Sample Clauses

Treatment validation. The treatment validation phase is an essential phase of the Design Science Cycle. In this phase, the artefact that was designed undergoes a validation process to confirm that it fits the specified requirements from the treatment design. If the artefact is not deemed suitable, the artefact should be re-designed based on the feedback from this phase. An artefact can be validated in many ways, for example, through an expert interview or an open case study [21]. In the case of this research, the RDFs representing the scenarios have been validated and also the scenarios. The created RDFs should be validated both on their structure as well as their semantics. The structure of the RDF can be validated using an RDF validator, which will check if the structure is correct, so that if certain characters are expected and not present, an error message is accordingly given. The semantics are a bit more complex to validate. When the ODRL translator [30] described in Section 2.3 is fully developed it could be used to translate the RDF back into natural language, and the natural language and the scenario of the use case can then be compared for correspondence. Furthermore, an ODRL expert could take a look at the RDFs and give their opinion on it. However, the ODRL expert might not be familiar with other vocabularies within the ODRL. Moreover, an AI tool can be asked to interpret the RDF. Since the RDFs are meant to be machine-readable, an AI tool should be able to interpret the offers and requests and should be able to decide whether an agreement should be created. The latter is our chosen validation method and ChatGPT 4 is used to validate our RDFs [31]. Furthermore, the scenarios themselves have also been validated. This has been done by conducting a survey on stakeholders in a real life FDT use case that the scenario from Section 4.8 is based upon. Since the stakeholders have experience with the FDT and offers and requests, they were able to tell whether the scenarios are relevant and realistic. Furthermore, these stakeholders also reviewed the created RDFs and gave feedback on them. In case that it appears that a designed artefact is not suitable according to the validation, the artefact should be redesigned and revalidated. However, this was not the case in this thesis.
Sample 1
AutoNDA by SimpleDocs

Related to Treatment validation

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Treatment The Asset Representations Reviewer agrees to hold and treat Confidential Information given to it under this Agreement in confidence and under the terms and conditions of this Section 4.08, and will implement and maintain safeguards to further assure the confidentiality of the Confidential Information. The Confidential Information will not, without the prior consent of the Issuer and the Servicer, be disclosed or used by the Asset Representations Reviewer, or its officers, directors, employees, agents, representatives or affiliates, including legal counsel (collectively, the “Information Recipients”) other than for the purposes of performing Reviews of Review Receivables or performing its obligations under this Agreement. The Asset Representations Reviewer agrees that it will not, and will cause its Affiliates to not (i) purchase or sell securities issued by the Seller or its Affiliates or special purpose entities on the basis of Confidential Information or (ii) use the Confidential Information for the preparation of research reports, newsletters or other publications or similar communications.

  • Validation Mechanism To be eligible for articulation, the student must show evidence of their CompTIA A+ certification and it must have been issued within three (3) years prior to their enrollment in the program.

  • Treatment of Fees The fees described in this Section 5 (a) are not compensation for the use, detention, or forbearance of money, (b) are in addition to, and not in lieu of, interest and expenses otherwise described in this Agreement, (c) are payable in accordance with Section 3.1(c), (d) are non-refundable, and (e) to the fullest extent permitted by Law, bear interest, if not paid when due, at the Default Rate.

  • Denial of Preferential Tariff Treatment The Customs Authority of the importing Party may deny a claim for preferential tariff treatment when: (a) the good does not qualify as an originating good; or (b) the importer, exporter or producer fails to comply with any of the relevant requirements of this Chapter.

  • Contracts (Rights of Third Parties) Xxx 0000 No term of this Agreement is enforceable under the Contracts (Rights of Third Parties) Xxx 0000 by a person who is not a party to this Agreement.

  • Future Treatment of Unallowable Costs Unallowable Costs shall be separately determined and accounted for by Defendants, and Defendants shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by Defendants or any of their subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.

  • Musculoskeletal Injury Prevention and Control The hospital in consultation with the Joint Health and Safety Committee (JHSC) shall develop, establish and put into effect, musculoskeletal prevention and control measures, procedures, practices and training for the health and safety of employees.

  • Medical Treatment Undersigned understands that the Released Parties do not have medical personnel available at the location of the activities. Undersigned hereby grants the Released Parties permission to administer first aid or to authorize emergency medical treatment, if necessary. Undersigned understands and agrees that any such action by the Released Parties shall be subject to the terms of this agreement and release, including any liability arising from the negligence of the Released Parties when administering first aid or authorizing others to do so. Undersigned understands and agrees that the Released Parties do not assume responsibility for any injury or damage which might arise out of or in connection with such authorized emergency medical treatment.

  • Emergency Medical Treatment I grant the Releasees permission to authorize emergency medical treatment as they deem appropriate, and agree that such action by the Releasees shall be subject to the terms of this Agreement. I understand and agree that the Releasees assume no responsibility for any injury or damage that might result from such emergency medical treatment.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!